Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
PHILADELPHIA, Nov. 28, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at 8:20 a.m. ET in Miami, FL.
Related news for (CABA)
- Cabaletta Bio Announces Proposed Public Offering of Securities
- Cabaletta Bio Announces Pricing of Public Offering of Securities
- Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
- Breaking News: MoBot’s Latest Update as of 05/16/25 06:00 AM
- Breaking News: MoBot’s Latest Update as of 05/16/25 05:00 AM